5.5 | | Dppa4 | 'stabilization-competent' vs 'stabilization-incompetent' in '23 day; secondary reprogramming cell' | age, cell type, phenotype | Transcription profiling by high throughput sequencing in gene expresion profile of 4 SC clones and 4 SI clones at different time points defined a stabilization competency signiture |
-5.2 | | Dppa4 | '10 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
4.8 | | Dppa4 | 'V6.5; embryonic stem cell’ vs 'wild type; endothelial' | cell line, cell type, genotype | CD47 Inhibits Self-renewal and Reprogramming by Regulating c-Myc and Other Stem Cell Transcription Factors |
4.6 | | Dppa4 | 'stabilization-competent' vs 'stabilization-incompetent' in '22 day; secondary reprogramming cell' | age, cell type, phenotype | Transcription profiling by high throughput sequencing in gene expresion profile of 4 SC clones and 4 SI clones at different time points defined a stabilization competency signiture |
-4.5 | | Dppa4 | '7 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
-4.5 | | Dppa4 | '4 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
-4.5 | | Dppa4 | 'alpha-amanitin; maternal Ring1-Rnf+' vs 'none; maternal Ring1-Rnf+' | compound, genotype | Polycomb function during oogenesis is required for mouse early embryonic development (2-cell embryos) |
-3.9 | | Dppa4 | '6 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
-3.8 | | Dppa4 | '3 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
3.7 | | Dppa4 | "98 to 119 week; reproductively old" vs "6 to 12 week; reproductively young" | age, phenotype | RNAseq of whole ovarian follicles from young and old mice. |
-3.6 | | Dppa4 | '26 day' vs '0 day' | age | Gene expression profile of mouse differentiating embryonic stem cells (day 0, 6, 16, and 26) |
-3.4 | | Dppa4 | '336 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-3.3 | | Dppa4 | '5 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
-3.2 | | Dppa4 | '16 day' vs '0 day' | age | Gene expression profile of mouse differentiating embryonic stem cells (day 0, 6, 16, and 26) |
-2.9 | | Dppa4 | 'metaphase II oocyte' vs 'germinal vesicle oocyte' | cell type | Transcription profiling of mouse in vivo matured MII oocytes and fully in vivo grown germinal vesicle oocytes to identify gene transcripts linked to epigenetic reprogramming |
-2.7 | | Dppa4 | '168 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
-2.7 | | Dppa4 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'mix of orthochromatic and polychromatophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
-2.7 | | Dppa4 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'basophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
-2.5 | | Dppa4 | 'adult definitive erythroid cell' vs 'primitive erythroid cell' in 'proerythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
2.4 | | Dppa4 | 'M-27; over-expressing IGF-IR' vs 'M-27; wild type' | cell line, genotype | Transcription profiling of wild_type and IGF-I receptor over-expressing mouse lung carcinoma cells identifies a type I insulin like growth factor receptor regulated gene expression profile associated with an altered site-specificity of metastasis. |
2.4 | | Dppa4 | 'Cbfb+/MYH11' vs 'control of Cbfb+/MYH11' | genotype | Transcription profiling by array of Mus musculus expressing Cbfb-MYH11 |
-2.4 | | Dppa4 | 'fetal definitive erythroid cell' vs 'primitive erythroid cell' in 'basophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
2.3 | | Dppa4 | '19BL; differentiated 3factor-reprogrammed induced pluripotent stem cell' vs 'R1; differentiated embryonic stem cell' at '5 day' | cell line, growth condition, time | Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines |
-2.2 | | Dppa4 | 'Ckit negative' vs 'Ckit positive' | cell type | Gene expression profile of c-kit positive and c-kit negative cells |
-2.2 | | Dppa4 | 'fetal definitive erythroid cell' vs 'primitive erythroid cell' in 'proerythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
-2.1 | | Dppa4 | '96 hour' vs '0 hour' on 'Affymetrix Mouse430A_2 Array' | time | Transcription profiling of murine V6.5 embryonic stem cells differentiating into embryoid bodies over a time-course to study changes in transcription during stem cell differentiation |
2.1 | | Dppa4 | '19BL; differentiated 3factor-reprogrammed induced pluripotent stem cell' vs 'R1; differentiated embryonic stem cell' at '11 day' | cell line, growth condition, time | Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines |
-1.9 | | Dppa4 | 'Kin-' vs 'wild type' in 'cAMP' at '24 hour' | compound, genotype, time | Transcription profiling by array of mouse S49 cells mutant for Kin after treatment with cAMP |
-1.7 | | Dppa4 | 'embryoid body' vs 'embryonic stem cell' on 'Affymetrix GeneChip Array 430A 2.0' | developmental stage | Gene expression profile of J1 embryonic stem cells and J1 embryoid bodies |
1.6 | | Dppa4 | '0.45 micromolar; 5-fluourouracil' vs 'none' at '24 hour' | compound, time | Transcription profiling by array of mouse embryonic stem cells after treatment with 5-fluourouracil, methoxyacetic acid, monobutl phthalate, Penicillin G, retinoic acid or valproic acid |
-1.6 | | Dppa4 | 'fetal definitive erythroid cell' vs 'primitive erythroid cell' in 'mix of orthochromatic and polychromatophilic erythroblast' | cell type, phenotype | Transcription profiling by array of differentiating primary primitive and definitive mouse red blood cells |
1.5 | | Dppa4 | '8.5 millimolar; methoxyacetic acid' vs 'none' at '24 hour' | compound, time | Transcription profiling by array of mouse embryonic stem cells after treatment with 5-fluourouracil, methoxyacetic acid, monobutl phthalate, Penicillin G, retinoic acid or valproic acid |
1.5 | | Dppa4 | 'Sohlh2-/-' vs 'wild type' | genotype | Transcription profiling by array of testis from Sohlh1 and Sohlh2 knock out mice |
1.5 | | Dppa4 | 'stabilization-competent' vs 'stabilization-incompetent' in '21 day; secondary reprogramming cell' | age, cell type, phenotype | Transcription profiling by high throughput sequencing in gene expresion profile of 4 SC clones and 4 SI clones at different time points defined a stabilization competency signiture |
1.5 | | Dppa4 | 'dmrt1 knockout' vs 'wild type' | genotype | Dmrt1 (doublesex and mab-3 related transcription factor 1) conditional knockout expression analysis of E15.5 ovaries. |
1.4 | | Dppa4 | 'Sohlh1-/-' vs 'wild type' | genotype | Transcription profiling by array of testis from Sohlh1 and Sohlh2 knock out mice |
1.3 | | Dppa4 | '0.8 millimolar; valproic acid' vs 'none' at '24 hour' | compound, time | Transcription profiling by array of mouse embryonic stem cells after treatment with 5-fluourouracil, methoxyacetic acid, monobutl phthalate, Penicillin G, retinoic acid or valproic acid |
-1.3 | | Dppa4 | '2 day' vs '0 day' | age | Transcription profiling of mouse embyronic stem cell line CGR8 during the first 10 days of differentiation into embryoid bodies |
1.3 | | Dppa4 | 'stabilization-competent' vs 'stabilization-incompetent' in '27 day; secondary reprogramming cell' | age, cell type, phenotype | Transcription profiling by high throughput sequencing in gene expresion profile of 4 SC clones and 4 SI clones at different time points defined a stabilization competency signiture |
-1.3 | | Dppa4 | 'retinoic acid' vs 'none' in 'embryoid body' at '8 day' | age, compound, phenotype | Transcription profiling of mouse embryonic stem cell line Sox1Tv2 during neuronal differentiation |
-1.2 | | Dppa4 | 'recombinant human interleukin-2; 100 unit per milliliter; 6 hour' vs 'control; 0 hour' | compound, time | Transcription profiling by array of mouse CTLL-2 cell line treated with recombinant human interleukin-2 |
-1.2 | | Dppa4 | 'Stella maternal / zygotic knockout' vs 'wild type genotype' in '2-cell embryo' | developmental stage, genotype | Transcription profiling of wild type and Stella knockout oocytes, wild type and Stella maternal/zygotic knockout embryos to study to the role of Stella in early mouse development |
-1.1 | | Dppa4 | 'induced neuronal cell' vs 'pluripotent embryonic stem cell' | phenotype | Transcription profiling by high throughput sequencing of retinoic acid-differentiated neuronal cells compared to nondifferentiated pluripotent embryonic stem cells |
1.1 | | Dppa4 | 'tristetrapolin knockout' vs 'wild type' in 'actinomycin D' at '90 minute' | compound, genotype, time | Transcription profiling by array of fibroblasts from TTP knock out mice |
-1 | | Dppa4 | 'recombinant human interleukin-2; 100 unit per milliliter; 12 hour' vs 'control; 0 hour' | compound, time | Transcription profiling by array of mouse CTLL-2 cell line treated with recombinant human interleukin-2 |